Treating a hormone-dependent cancer
Some breast and prostate cancers rely on hormone signals. Endocrine treatment reduces hormone production or blocks its action. It is different from hormone replacement and from cytotoxic chemotherapy. In breast cancer, estrogen and progesterone receptor results guide its role; in prostate cancer, androgen deprivation often provides the treatment backbone.
Source [1]
The tests and context that matter
For breast cancer, menopausal status, recurrence risk, prior endocrine exposure and the pace of disease affect the choice. In advanced disease, ESR1, PIK3CA and other relevant alterations may guide a partner drug or a later endocrine strategy. A positive receptor result does not mean every endocrine medicine will keep working indefinitely.
For prostate cancer, distinguish hormone-sensitive from castration-resistant disease. Testosterone measurements, PSA trends, imaging and prior androgen-receptor medicines help interpret progression.
Breast cancer: receptor status is only the first layer
An aromatase inhibitor lowers estrogen production; tamoxifen blocks receptor signaling; other drugs degrade the receptor. Ovarian function changes how these options are used. In someone who has not reached menopause, an aromatase inhibitor is not simply interchangeable with tamoxifen without considering ovarian suppression.
Prostate cancer: resistance does not mean hormones are irrelevant
Castration resistance means progression despite sufficiently suppressed testosterone. It is not established by a single PSA result alone. Further treatment may build on continuing androgen deprivation; ask which component is being retained, added or replaced and why.
Global treatment frontiers
Endocrine treatment is moving from a fixed sequence toward decisions informed by emerging resistance. In September 2026, the FDA granted accelerated approval to camizestrant with a CDK4/6 inhibitor when an ESR1 mutation is detected during aromatase-inhibitor plus CDK4/6 treatment for HR-positive/HER2-negative advanced breast cancer. This makes the timing of molecular testing part of the treatment decision.
CDK4/6 combinations also illustrate how regional development can add to a global treatment class. China’s DAWNA-2 trial showed that adding dalpiciclib to an aromatase inhibitor delayed progression compared with the aromatase inhibitor alone. It did not compare dalpiciclib directly with other CDK4/6 inhibitors; previous treatment, biomarkers and tolerability remain central to choosing among them.
A resistance signal before scan progression
SERENA-6 studied switching after an ESR1 change before clinical progression, while continuing the CDK4/6 inhibitor. The resulting accelerated approval offers a molecularly guided pathway for the defined population. Discuss when ESR1 testing is useful and arrange the cardiac monitoring required for the proposed regimen.
Long-term treatment with scheduled review
Tablets, injections and sometimes surgery to suppress hormone production have different practical demands. Treatment may last years in an adjuvant setting. For advanced cancer, duration and combinations are reassessed according to benefit and tolerability.
Write down all medicines and supplements. Missed tablets, injection timing and drug interactions can affect treatment. Persistent side effects deserve an adjustment discussion; stopping alone can remove useful cancer control.
Review the burden as carefully as the cancer
Treatment that lasts months or years needs a workable follow-up plan. Persistent symptoms should lead to a discussion about management or alternatives, not silent discontinuation.
- Keep a record of tablet use and injection dates.
- Ask whether bone-density, metabolic or cardiovascular review is relevant to your medicine.
- Discuss sexual symptoms, sleep and fertility concerns before they undermine adherence.
Protecting bone, metabolism and quality of life
Hot flushes, sexual symptoms, joint pain and fatigue can affect adherence. Some therapies reduce bone density or alter metabolic and cardiovascular risk; others have clotting or endometrial risks. Monitoring should match the medicine, rather than applying the same checklist to everyone. Bone health, exercise, symptom management and fertility concerns belong in the treatment plan.
Estimated total treatment cost
Costs depend on whether treatment uses a hormone medicine alone or combines it with other medicines. The ranges below cover the named treatment plans.
| Treatment plan | Estimated total cost |
|---|---|
| Oral hormone therapy alone, such as letrozole | US$2,000–7,000 |
| Prostate cancer: ADT + abiraterone or apalutamide | US$5,000–20,000 |
| Breast cancer: hormone therapy + abemaciclib | US$6,000–25,000 |
What’s included
These are estimates of total medical treatment costs for the listed treatment plans. In addition to the named medicines, they include specialist consultations and assessment, pretreatment tests, routine laboratory and imaging follow-up as needed, treatment administration and nursing where applicable, necessary hospitalization and monitoring, and routine supportive care. Travel and accommodation are not included.
Your individual treatment costs
Hormone therapy often requires ongoing treatment. Some plans have a defined duration, while others continue according to disease control and tolerability. Costs accumulate with actual use; these ranges do not represent the full cost of years of treatment. This range is indicative only; your individual costs may fall outside it. Contact us for a personalized cost estimate based on your medical needs and specialist assessment.
Evidence & sources
Prepared by Chirona’s content team from the sources below. This guide supports a discussion with your treating team; it does not determine an individual treatment plan.